AMGN AMGEN INC
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 318154 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY8.2%
TTM net income YoY34.1%
TTM EPS YoY33.4%
Revenue 3-yr CAGR13.2%
Net income 3-yr CAGR7.5%
Margins
Gross margin70.9%
Operating margin32.4%
Net margin24.1%
FCF margin24.6%
EBITDA margin39.4%
Returns
ROE78.4%
ROA10.1%
ROIC (approx.)19.5%
Asset turnover0.42x
Leverage & solvency
Liabilities / assets85.1%
Debt / equity3.76x
Current ratio1.48x
Interest coverage4.78x
Cash quality & payout
Operating cash flow / net income1.28x
Accruals ratio-2.8%
Payout ratio57.1%
Capex / revenue6.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $10.37B | $10.05B | $8.62B | $9.87B | $9.56B | $9.18B | $8.15B | $9.09B |
| Cost of revenue | $2.79B | $2.81B | $2.74B | $2.98B | $3.08B | $3.01B | $2.97B | $3.11B |
| Gross profit | $7.58B | $7.24B | $5.87B | $6.89B | $6.47B | $6.17B | $5.18B | $5.97B |
| R&D expense | $2.11B | $1.87B | $1.72B | $2.14B | $1.90B | $1.74B | $1.49B | $1.72B |
| SG&A expense | $1.68B | $1.75B | $1.60B | $1.95B | $1.72B | $1.69B | $1.69B | $1.88B |
| Operating income | $3.71B | $3.51B | $2.67B | $2.72B | $2.53B | $2.66B | $1.18B | $2.31B |
| Interest expense | $653.00M | $673.00M | $657.00M | $653.00M | $685.00M | $694.00M | $723.00M | $747.00M |
| Pretax income | $4.69B | $2.77B | $2.08B | $1.51B | $3.92B | $1.57B | $1.97B | $782.00M |
| Income tax | $822.00M | $393.00M | $265.00M | $181.00M | $705.00M | $136.00M | $243.00M | $155.00M |
| Net income | $3.86B | $2.38B | $1.82B | $1.33B | $3.22B | $1.43B | $1.73B | $627.00M |
| EBITDA | $3.94B | $3.74B | $3.78B | $3.85B | $2.76B | $2.88B | $2.56B | $3.71B |
| EPS (basic) | 7.14 | 4.40 | 3.37 | — | 5.98 | 2.66 | 3.22 | — |
| EPS (diluted) | 7.08 | 4.37 | 3.34 | — | 5.93 | 2.65 | 3.20 | — |
| Dividends declared per share | 2.52 | 2.52 | 2.52 | 2.52 | 2.38 | 2.38 | 2.38 | 2.25 |
| Weighted avg. shares (diluted) | 546.00M | 544.00M | 544.00M | — | 542.00M | 541.00M | 541.00M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $13.19B | $13.99B | $12.04B | $9.13B | $9.45B | $8.03B | $8.81B | $11.97B |
| Receivables | $10.35B | $10.23B | $9.14B | $9.57B | $8.49B | $8.70B | $8.13B | $6.78B |
| Inventory | $6.39B | $6.22B | $6.19B | $6.22B | $6.35B | $6.58B | $6.73B | $7.00B |
| Current assets | $34.36B | $34.96B | $31.48B | $29.06B | $27.89B | $26.73B | $26.93B | $29.03B |
| PP&E, net | $8.88B | $8.55B | $8.22B | $7.91B | $7.22B | $6.86B | $6.68B | $6.54B |
| Goodwill | $18.66B | $18.67B | $18.67B | $18.68B | $18.68B | $18.67B | $18.64B | $18.64B |
| Intangibles | $19.54B | $20.49B | $21.38B | $22.28B | $23.14B | $24.61B | $25.72B | $27.70B |
| Total assets | $96.05B | $95.64B | $92.50B | $90.59B | $90.14B | $87.90B | $89.37B | $91.84B |
| Current liabilities | $23.23B | $25.50B | $24.95B | $25.49B | $21.79B | $20.48B | $23.01B | $23.10B |
| Short-term debt | $2.40B | $5.45B | $5.44B | $4.60B | $2.15B | $2.44B | $3.37B | $3.55B |
| Long-term debt | $51.61B | $51.86B | $51.89B | $50.01B | $52.43B | $53.76B | $54.01B | $56.55B |
| Total debt | $54.01B | $57.30B | $57.32B | $54.60B | $54.59B | $56.20B | $57.38B | $60.10B |
| Total liabilities | $81.70B | $83.95B | $83.31B | $81.93B | $80.52B | $80.47B | $83.16B | $85.96B |
| Shareholders' equity | $14.35B | $11.69B | $9.19B | $8.66B | $9.62B | $7.43B | $6.21B | $5.88B |
| Net debt | $40.82B | $43.31B | $45.28B | $45.48B | $45.14B | $48.18B | $48.57B | $48.13B |
| Shares outstanding | 540.90M | 540.60M | 539.70M | 538.80M | 538.50M | 538.30M | 537.70M | 536.90M |
| Cash flow statement | ||||||||
| Operating cash flow | $4.24B | $4.00B | $2.19B | $1.60B | $4.68B | $2.28B | $1.39B | $4.77B |
| Capital expenditure | $587.00M | $513.00M | $712.00M | $642.00M | $436.00M | $369.00M | $411.00M | $371.00M |
| Free cash flow | $3.65B | $3.49B | $1.48B | $961.00M | $4.25B | $1.91B | $980.00M | $4.40B |
| Investing cash flow | -$649.00M | -$569.00M | -$716.00M | -$693.00M | -$414.00M | -$389.00M | -$447.00M | -$402.00M |
| Financing cash flow | -$4.39B | -$1.48B | $1.44B | -$1.23B | -$2.85B | -$2.67B | -$4.11B | -$1.41B |
| Depreciation & amortization | $233.00M | $222.00M | $1.12B | $1.13B | $232.00M | $220.00M | $1.39B | $1.40B |
| Stock-based compensation | $128.00M | $165.00M | $75.00M | $125.00M | $127.00M | $157.00M | $85.00M | $134.00M |
| Dividends paid | $1.36B | $1.36B | $1.36B | $1.28B | $1.28B | $1.28B | $1.28B | $1.21B |
Free plan shows the latest 8 periods; Pro shows all 74 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.